Clostridium difficile infections have been noted by EU and US health authorities as an ‘emerging’ healthcare threat – costing the US $1bn annually. Now, researchers preparing a pilot study are looking at whether probiotics...

Research, focus and regulatory cunning will be needed if the nutraceutical industry is to tap into the relatively unexplored area of non-alcoholic fatty liver disease (NAFLD), says the consultancy firm...